BOTHELL, Wash.--(BUSINESS WIRE)--Mirabilis Medica, a privately-held medical device company, today announced completion of its first human trial, which served as a preliminary demonstration of clinical feasibility of its prototype High Intensity Focused Ultrasound (HIFU) system for treatment of uterine fibroids. Volunteer patients were treated with the Mirabilis system just prior to scheduled hysterectomies, after which the excised uterine tissue was examined by a pathologist for effects of treatment. This analysis demonstrated successful creation of lesions within the target zone.
